

Medical Policy

Autologous Chondrocyte Implantation

Policy Number: 1063

Policy History			
Approve Date:	10/20/2016	Effective Date:	10/20/2016
Reviewed/Revised Dates:	10/20/2017, 10/20/2018, 07/15/2019, 12/07/2020		

Preauthorization	
All Plans	Benefit plans vary in coverage and some plans may not provide coverage for certain service(s) listed in this policy. Decisions for authorization are subject to all terms and conditions of the applicable benefit plan, including specific exclusions and limitations as well as applicable state and/or federal laws. Please review the benefit plan descriptions for details.

Policy

Indications of Coverage

- I. WEA Trust considers autologous chondrocyte implants medically necessary for repairing cartilage effects of the knee when the following selection criteria are met.
 - A. Member has symptoms of disabling knee pain related to a full thickness, focal chondral defect with all of the following:
 - i. Age of 15 - 60 years AND
 - ii. Body mass index (BMI) less than or equal to 35 AND
 - iii. Failure of conservative therapy (minimum of two months of physical therapy) as well as established surgical interventions (i.e. microfraction, drilling, abrasion or osteochondral autograft) (diagnostic arthroscopy, lavage or debridement is not considered adequate to meet this criterion) AND
 - iv. Focal articular cartilage defect is down to but not through the subchondral bone on a load bearing surface of the femoral condyle (medial, lateral, trochlear – but not in the patella AND
 - v. Has no active inflammatory or other arthritis, including degenerative arthritis (osteoarthritis) clinically and by x-ray AND
 - vi. Has disabling pain and/or knee locking which limits activities of daily living AND
 - vii. The size of defect measures less than 7 mm in depth, less than 6.0 cm in length, and area ranging from 1.6 to 10 square centimeters (cm) AND
 - viii. There is stable and aligned knee with intact meniscus and normal joint space on x-ray (a corrective procedure in combination with, or prior to, chondrocyte implantation may be necessary to ensure stability, alignment and normal weight distribution within the joint).

- II. WEA Trust considers autologous chondrocyte implants experimental and investigational for all other indications because effectiveness has not been established for any other indication including but not limited to the following:
 - A. Individuals with a patellar or talar lesion or lesions of other joints (e.g. hip and shoulder) OR
 - B. Individuals who have had a previous total menisectomy OR

- C. Individuals with a cartilaginous defect associated with osteoarthritis, rheumatoid arthritis or inflammatory disease or where an osteoarthritic or inflammatory process significantly and adversely affects the quality of the peri lesional cartilage OR
 - D. Individuals with a known history of anaphylaxis to gentamicin or sensitivities to materials of bovine origin OR
 - E. Individuals with osteochondritis dissecans (OCD) lesions OR
 - F. Initial or first line of surgical therapy.
- III. WEA considers matrix-induced chondrocyte implantation including the use of Bio-Gide (resorbable bilayer membrane made of porcine collagen) experimental and investigational for all indications including autologous chondrocyte implantation of the knee because its efficacy has not been established in peer reviewed literature.
- IV. WEA Trust considers combined meniscal allograft and autologous chondrocyte implantation of the knee experimental and investigational as efficacy has not been established in peer reviewed literature.
- V. WEA Trust considers combination of autologous chondrocyte implantation and osteochondral autograft transfer system for surgical repair of cartilage defects of the knee experimental and investigational because efficacy has not been established in peer reviewed literature.

Background

Articular cartilage damaged through acute or chronic trauma or osteochondritis dessecans, has limited ability to regenerate, leading to the symptoms of pain, restricted mobility and locking. Current treatment methods to stimulate repair of the cartilage include shaving the margins of the damaged cartilage to remove mechanical obstructions or irritants (abrasion or debridement) or drilling through the cartilage through the underlying bone into the vascular marrow in order to permit the ingrowth of fibrocartilage from the marrow. Long-standing severe damage to the articular cartilage can lead to debilitating osteoarthritis, which ultimately may require a total knee arthroplasty.

Autologous chondrocyte implants (autologous chondrocyte transplant) (Carticel, Genzyme Inc., Cambridge, MA) has been investigated as a means of a 3-step treatment for repairing cartilage defects in the knee. First, normal cartilage is harvested from a joint margin during an arthroscopic biopsy procedure. This biopsy of an articular surface serves as the source of cultured chondrocytes. This specimen of live articular cartilage is placed into a culture medium. Under a strictly controlled environment the cells are separated from the cartilage. These cells are then multiplied using a cell-culture technique. They are stored in the frozen state and are thawed and have a final culturing process before they are shipped to the operating room on the day of the implantation. It takes about 6 weeks to culture chondrocytes for implantation. Approximately 12 million cartilage cells are present in the 0.4ml medium that is ultimately implanted into the defect. The cultured chondrocytes are implanted into the cartilage defect in a second open arthrotomy procedure.

Patients are referred for autologous chondrocyte implantation after already having had surgery for an articular cartilage problem. If the patient remains symptomatic, and the patient and the surgeon decide that autologous chondrocyte implant is the best option, then an arthroscopic biopsy is planned.

Ideally, candidates for autologous chondrocyte implant should be between 15 and 60 years of age, have full thickness localized defects of the femoral condyles, have intact menisci, have no generalized chondromalacia, have no limb mis-alignment and are willing and able to undergo vigorous rehabilitation. This procedure is not recommended for patients who have an unstable knee and for patients sensitive to materials of bovine origins. It is also not recommended for use in children, and not yet in any joint other than the knee.

References

1. McPherson JM, Tubo R, Barone L. Chondrocyte transplantation. *Arthroscopy*. 1997;13(4):541-547.
2. Minas T, Nehrer S. Current concepts in the treatment of articular cartilage defects. *Orthopedics*. 1997;20(6):525-538.
3. Rudert M, Wirth CJ. Cartilage cell transplantation. Experimental principles and clinical applications. *Orthopade*. 1997;26(8):741-747.
4. Wright JG. Autologous chondrocyte transplantation. *N Engl J Med*. 1995;332(8):540.
5. Brittberg M, Lindahl A, Nilsson A, et al. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. *N Engl J Med*. 1994;331(14):889-895.
6. Mankin HJ. Chondrocyte transplant - One answer to an old question. *N Engl J Med*. 1994;331:940-941.
7. Robinson D, Ash H, Aviezer D, et al. Autologous chondrocyte transplantation for reconstruction of isolated joint defects: The Assaf Harofeh experience. *Isr Med Assoc J*. 2000;2(4):290-295.
8. O'Driscoll SW. Technical considerations in periosteal grafting for osteochondral injuries. *Clin Sports Med*. 2001;20(2):379-402, vii.
9. Alleyne KR, Galloway MT. Management of osteochondral injuries of the knee. *Clin Sports Med*. 2001;20(2):343-364.
10. Cain EL, Clancy WG. Treatment algorithm for osteochondral injuries of the knee. *Clin Sports Med*. 2001;20(2):321-342.
11. Jobanputra P, Parry D, Fry-Smith A, et al. Effectiveness of autologous chondrocyte transplantation for hyaline cartilage defects in knees: A rapid and systematic review. *Health Technol Assess*. 2001;5(11):1-57.
12. State of Minnesota, Health Technology Advisory Committee (HTAC). Autologous chondrocyte implantation for chondral knee damage. Issue Brief. St. Paul, MN: HTAC; September 1999.
13. National Institute for Clinical Excellence (NICE). Guidance on the use of autologous cartilage transplantation for full thickness cartilage defects in knee joints. Technology Appraisal Guidance No. 16. London, UK: NICE; 2000.
14. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. *Arthritis Rheum*. 2000;43(9):1905-1915.
15. Mont MA, Jones LC, Vogelstein BN, Hungerford DS. Evidence of inappropriate application of autologous cartilage transplantation therapy in an uncontrolled environment. *Am J Sports Med*. 1999;27(5):617-620.
16. Peterson L, Brittberg M, Kiviranta I, et al. Autologous chondrocyte transplantation. Biomechanics and long-term durability. *Am J Sports Med*. 2002;30(1):2-12.
17. Giannini S, Vannini F, Buda R. Osteoarticular grafts in the treatment of OCD of the talus: Mosaicplasty versus autologous chondrocyte transplantation. *Foot Ankle Clin*. 2002;7(3):621-633.
18. Koulalis D, Schultz W, Heyden M. Autologous chondrocyte transplantation for osteochondritis dissecans of the talus. *Clin Orthop*. 2002;(395):186-192.
19. Giannini S, Buda R, Grigolo B, Vannini F. Autologous chondrocyte transplantation in osteochondral lesions of the ankle joint. *Foot Ankle Int*. 2001;22(6):513-517.
20. Hayes DW Jr, Averett RK. Articular cartilage transplantation. Current and future limitations and solutions. *Clin Podiatr Med Surg*. 2001;18(1):161-176.
21. Swedish Council on Technology Assessment in Health Care (SBU). Autologous chondrocyte transplantation in treating cartilage damage in the knee - early assessment briefs (ALERT). Stockholm, Sweden: SBU; November 1999. Available at: <http://www.sbu.se/www/index.asp>. Accessed April 27, 2004.
22. Jobanputra P, Parry D, Fry-Smith A, Burls A. Effectiveness of autologous chondrocyte transplantation for cartilage defects in the knees: A rapid and systematic review. Birmingham, UK: West Midlands Health Technology Assessment Collaboration (WMHTAC), Department of Public Health and Epidemiology, University of Birmingham; 2001. Available at: <http://www.publichealth.bham.ac.uk/wmhtac/reports.htm>. Accessed April 27, 2004.
23. Washington State Department of Labor and Industries, Office of the Medical Director. Autologous chondrocyte implantation (ACI): 2002 update. Technology Assessment. Olympia, WA: Washington State

- Department of Labor and Industries; updated June 26, 2002. Available at: <http://www.lni.wa.gov/omd/TechAssessDocs.htm>. Accessed August 7, 2003.
24. BlueCross BlueShield Association (BCBSA), Technology Evaluation Center (TEC). Autologous chondrocyte transplantation of the knee. TEC Assessment Program. Chicago IL: BCBSA; June 2003; 18(2). Available at: http://www.bcbs.com/tec/vol18/18_02.html. Accessed April 27, 2004.
 25. Bentley G, Biant LC, Carrington RW, et al. A prospective, randomised comparison of autologous chondrocyte implantation versus mosaicplasty for osteochondral defects in the knee. *J Bone Joint Surg Br.* 2003;85(2):223-230.
 26. Horas U, Pelinkovic D, Herr G, et al. Autologous chondrocyte implantation and osteochondral cylinder transplantation in cartilage repair of the knee joint. A prospective comparative trial. *J Bone Joint Surg Am.* 2003;85:185–192.
 27. Knutsen G, Engebretsen L, Ludvigsen TC, et al. Autologous chondrocyte implantation compared with microfracture in the knee. A randomized trial. *J Bone Joint Surg Am.* 2004;86-A(3):455-464.
 28. Basad E, Sturz H, Steinmeyer J. First results of a comparative clinical study. The treatment of chondral defects with MACI. *MedReview.* 2004;1:25-26.
 29. Wasiak J, Clar C, Villanueva E. Autologous cartilage implantation for full thickness articular cartilage defects of the knee. *Cochrane Database Syst Rev.* 2006;(3):CD003323.
 30. Vasiliadis HS, Wasiak J. Autologous cartilage implantation for full thickness articular cartilage defects of the knee. *Cochrane Database Syst Rev.* 2010;(10):CD003323.
 31. National Institute for Health and Clinical Excellence (NICE). The use of autologous chondrocyte implantation for the treatment of cartilage defects in knee joints. Technology Appraisal 89. London, UK: NICE; May 2005.
 32. NHS Quality Improvement Scotland (NHS QIS). The use of autologous chondrocyte implantation for the treatment of cartilage defects in knee joints (review). Glasgow, Scotland: NHS QIS; 2005.
 33. Clar C, Cummins E, McIntyre L, et al. Clinical and cost-effectiveness of autologous chondrocyte implantation for cartilage defects in knee joints: Systematic review and economic evaluation. *Health Technol Assess.* 2005;(9):47:1-101.
 34. French National Authority for Health (HAS). Autologous chondrocyte implantation in the knee joint [summary]. Saint-Denis La Plaine, France: Haute Autorite de Sante/French National Authority for Health (HAS); 2005.
 35. Ruano-Ravina A, Jato M. Effectiveness and safety of the autologous chondrocyte implant (HTA report) [summary]. INF2005/01. Santiago de Compostela, Spain: Galician Agency for Health Technology Assessment (AVALIA-T); 2005.
 36. Ruano-Ravina A, Jato Diaz M. Autologous chondrocyte implantation: A systematic review. *Osteoarthritis Cartilage.* 2006;14(1):47-51.
 37. Dozin B, Malpeli M, Cancedda R, et al. Comparative evaluation of autologous chondrocyte implantation and mosaicplasty: A multicentered randomized clinical trial. *Clin J Sport Med.* 2005;15(4):220-226.
 38. Micheli L, Curtis C, Shervin N. Articular cartilage repair in the adolescent athlete: Is autologous chondrocyte implantation the answer? *Clin J Sport Med.* 2006;16(6):465-470.
 39. Mandelbaum B, Browne JE, Fu F, et al. Treatment outcomes of autologous chondrocyte implantation for full-thickness articular cartilage defects of the trochlea. *Am J Sports Med.* 2007;35(6):915-921.
 40. Farr J. Autologous chondrocyte implantation improves patellofemoral cartilage treatment outcomes. *Clin Orthop Relat Res.* 2007;463:187-194.
 41. Pérez Cachafeiro S, Ruano Raviña A; Autologous Chondrocyte Transplant Workgroup. Autologous chondrocyte implantation. An updated systematic review and tutelage use extension [summary]. AVALIA-T No. 2006/06. Madrid, Spain: Ministry of Health and Consumption; 2006.
 42. Magnussen RA, Dunn WR, Carey JL, Spindler KP. Treatment of focal articular cartilage defects in the knee: A systematic review. *Clin Orthop Relat Res.* 2008;466(4):952-962.
 43. Safran MR, Kim H, Zaffagnini S. The use of scaffolds in the management of articular cartilage injury. *J Am Acad Orthop Surg.* 2008;16(6):306-311.
 44. Minas T, Gomoll AH, Rosenberger R, et al. Increased failure rate of autologous chondrocyte implantation after previous treatment with marrow stimulation techniques. *Am J Sports Med.* 2009;37(5):902-908.
 45. Zaslav K, Cole B, Brewster R, et al. A prospective study of autologous chondrocyte implantation in patients with failed prior treatment for articular cartilage defect of the knee. *Am J Sports Med.* 2009;37(1):42-55.

46. Minas T, Bryant T. The role of autologous chondrocyte implantation in the patellofemoral joint. *Clin Orthop Relat Res*. 2005;(436):30-39.
47. Bartlett W, Skinner JA, Gooding CR, et al. Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee: A prospective, randomised study. *J Bone Joint Surg Br*. 2005;87(5):640-645.
48. Zheng MH, Willers C, Kirilak L, et al. Matrix-induced autologous chondrocyte implantation (MACI): Biological and histological assessment. *Tissue Eng*. 2007;13(4):737-746.
49. Ebert JR, Robertson WB, Lloyd DG, et al. Traditional vs accelerated approaches to post-operative rehabilitation following matrix-induced autologous chondrocyte implantation (MACI): Comparison of clinical, biomechanical and radiographic outcomes. *Osteoarthritis Cartilage*. 2008;16(10):1131-1140.
50. Safran MR, Kim H, Zaffagnini S. The use of scaffolds in the management of articular cartilage injury. *J Am Acad Orthop Surg*. 2008;16(6):306-311.
51. McNickle AG, L'Heureux DR, Yanke AB, Cole BJ. Outcomes of autologous chondrocyte implantation in a diverse patient population. *Am J Sports Med*. 2009;37(7):1344-1350.
52. Nam EK, Ferkel RD, Applegate GR. Autologous chondrocyte implantation of the ankle: A 2- to 5-year follow-up. *Am J Sports Med*. 2009;37(2):274-284.
53. Brittberg M. Cell carriers as the next generation of cell therapy for cartilage repair: A review of the matrix-induced autologous chondrocyte implantation procedure. *Am J Sports Med*. 2010;38(6):1259-1271.
54. Minas T, Gomoll AH, Solhpour S, et al. Autologous chondrocyte implantation for joint preservation in patients with early osteoarthritis. *Clin Orthop Relat Res*. 2010;468(1):147-157.
55. Kunzl M, Wild C, Mathis S, Johansson T. Autologous chondrocyte implantation. Summary. Decision Support Document 24. Vienna, Austria: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI HTA); December 2009.
56. Giza E, Sullivan M, Ocel D, et al. Matrix-induced autologous chondrocyte implantation of talus articular defects. *Foot Ankle Int*. 2010;31(9):747-753.
57. Ebert JR, Lloyd DG, Ackland T, Wood DJ. Knee biomechanics during walking gait following matrix-induced autologous chondrocyte implantation. *Clin Biomech (Bristol, Avon)*. 2010;25(10):1011-1017.
58. Benthien JP, Schwaninger M, Behrens P. We do not have evidence based methods for the treatment of cartilage defects in the knee. *Knee Surg Sports Traumatol Arthrosc*. 2011;19(4):543-552.
59. Genovese E, Ronga M, Angeretti MG, et al. Matrix-induced autologous chondrocyte implantation of the knee: Mid-term and long-term follow-up by MR arthrography. *Skeletal Radiol*. 2011;40(1):47-56.
60. Ebert JR, Robertson WB, Woodhouse J, et al. Clinical and magnetic resonance imaging-based outcomes to 5 years after matrix-induced autologous chondrocyte implantation to address articular cartilage defects in the knee. *Am J Sports Med*. 2011;39(4):753-763.
61. No authors listed. Autologous chondrocytes. Autologous chondrocyte implantation: More data needed. *Prescrire Int*. 2011;20(116):122-124.
62. Ossendorf C, Steinwachs MR, Kreuz PC, et al. Autologous chondrocyte implantation (ACI) for the treatment of large and complex cartilage lesions of the knee. *Sports Med Arthrosc Rehabil Ther Technol*. 2011;3:11.
63. Dixon S, Harvey L, Baddour E, et al. Functional outcome of matrix-associated autologous chondrocyte implantation in the ankle. *Foot Ankle Int*. 2011;32(4):368-374.
64. Schneider U, Rackwitz L, Andereya S, et al. A prospective multicenter study on the outcome of type I collagen hydrogel-based autologous chondrocyte implantation (CaReS) for the repair of articular cartilage defects in the knee. *Am J Sports Med*. 2011;39(12):2558-2565.
65. Enea D, Cecconi S, Busilacchi A, et al. Matrix-induced autologous chondrocyte implantation (MACI) in the knee. *Knee Surg Sports Traumatol Arthrosc*. 2012;20(5):862-869.
66. Filardo G, Kon E, Berruto M, et al. Arthroscopic second generation autologous chondrocytes implantation associated with bone grafting for the treatment of knee osteochondritis dissecans: Results at 6 years. *Knee*. 2012;19(5):658-663.
67. Niemeyer P, Salzmann G, Schmal H, et al. Autologous chondrocyte implantation for the treatment of chondral and osteochondral defects of the talus: A meta-analysis of available evidence. *Knee Surg Sports Traumatol Arthrosc*. 2012;20(9):1696-1703.

68. Pestka JM, Bode G, Salzmann G, et al. Clinical outcome of autologous chondrocyte implantation for failed microfracture treatment of full-thickness cartilage defects of the knee joint. *Am J Sports Med.* 2012;40(2):325-331.
69. Medical Services Advisory Committee (MSAC). Matrix-induced autologous chondrocyte implantation and autologous chondrocyte implantation. Assessment Report. MSAC Application 1140. Canberra, ACT: Medical Services Advisory Committee (MSAC); December 2010.
70. Jordan MA, Van Thiel GS, Chahal J, Nho SJ. Operative treatment of chondral defects in the hip joint: A systematic review. *Curr Rev Musculoskelet Med.* 2012;5(3):244-253.
71. Gross CE, Chalmers PN, Chahal J, et al. Operative treatment of chondral defects in the glenohumeral joint. *Arthroscopy.* 2012;28(12):1889-1901.
72. Petri M, Broese M, Simon A, et al. CaReS[®] (MACT) versus microfracture in treating symptomatic patellofemoral cartilage defects: A retrospective matched-pair analysis. *J Orthop Sci.* 2013;18(1):38-44.
73. Noyes FR, Barber-Westin SD. Advanced patellofemoral cartilage lesions in patients younger than 50 years of age: Is there an ideal operative option? *Arthroscopy.* 2013;29(8):1423-1436.
74. El Bitar YF, Lindner D, Jackson TJ, Domb BG. Joint-preserving surgical options for management of chondral injuries of the hip. *J Am Acad Orthop Surg.* 2014;22(1):46-56.
75. Rue JP, Yanke AB, Busam ML, et al. Prospective evaluation of concurrent meniscus transplantation and articular cartilage repair: Minimum 2-year follow-up. *Am J Sports Med.* 2008;36(9):1770-1778.
76. Harris JD, Cavo M, Brophy R, et al. Biological knee reconstruction: A systematic review of combined meniscal allograft transplantation and cartilage repair or restoration. *Arthroscopy.* 2011;27(3):409-418.
77. Harris JD, Siston RA, Pan X, Flanigan DC. Autologous chondrocyte implantation: A systematic review. *J Bone Joint Surg Am.* 2010;92(12):2220-2233.
78. Gomoll AH, Gillogly SD, Cole BJ, et al. Autologous chondrocyte implantation in the patella: A multicenter experience. *Am J Sports Med.* 2014;42(5):1074-1081.
79. Kalunian KC. Surgical therapy of osteoarthritis. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed December 2014.
80. Schmitt LC, Quatman CE, Paterno MV, et al. Functional outcomes after surgical management of articular cartilage lesions in the knee: A systematic literature review to guide postoperative rehabilitation. *J Orthop Sports Phys Ther.* 2014;44(8):565-A10.
81. Takahashi N, Ishiguro N. Regenerative medicine for cartilage defect in rheumatic disease. *Clin Calcium.* 2015;25(12):1801-1807.
82. Duif C, Koutah MA, Ackermann O, et al. Combination of autologous chondrocyte implantation (ACI) and osteochondral autograft transfer system (OATS) for surgical repair of larger cartilage defects of the knee joint. A review illustrated by a case report. *Technol Health Care.* 2015;23(5):531-537.
83. Oussedik S, Tsitskaris K, Parker D. Treatment of articular cartilage lesions of the knee by microfracture or autologous chondrocyte implantation: A systematic review. *Arthroscopy.* 2015;31(4):732-744.
84. Samsudin EZ, Kamarul T. The comparison between the different generations of autologous chondrocyte implantation with other treatment modalities: A systematic review of clinical trials. *Knee Surg Sports Traumatol Arthrosc.* 2015 May 24 [Epub ahead of print].